Idera

View All

transthyretin amyloidosis
Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a s...

Find More